MA49401A - Inhibiteurs de la kinase alk2 contenant de l'imidazole - Google Patents
Inhibiteurs de la kinase alk2 contenant de l'imidazoleInfo
- Publication number
- MA49401A MA49401A MA049401A MA49401A MA49401A MA 49401 A MA49401 A MA 49401A MA 049401 A MA049401 A MA 049401A MA 49401 A MA49401 A MA 49401A MA 49401 A MA49401 A MA 49401A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase
- inhibitors containing
- containing imidazole
- alk2 inhibitors
- alk2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762520150P | 2017-06-15 | 2017-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49401A true MA49401A (fr) | 2020-04-22 |
Family
ID=64659499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049401A MA49401A (fr) | 2017-06-15 | 2018-06-14 | Inhibiteurs de la kinase alk2 contenant de l'imidazole |
Country Status (17)
Country | Link |
---|---|
US (2) | US11661426B2 (fr) |
EP (1) | EP3638229A4 (fr) |
JP (2) | JP7257338B2 (fr) |
CN (1) | CN110913855A (fr) |
AR (1) | AR112027A1 (fr) |
AU (2) | AU2018283053C1 (fr) |
BR (1) | BR112019026517A2 (fr) |
CA (1) | CA3066164A1 (fr) |
CL (1) | CL2019003669A1 (fr) |
CO (1) | CO2020000194A2 (fr) |
EA (1) | EA202090052A1 (fr) |
IL (1) | IL271109A (fr) |
MA (1) | MA49401A (fr) |
MX (2) | MX2019015226A (fr) |
PH (1) | PH12019502781A1 (fr) |
SG (1) | SG10202112496SA (fr) |
WO (1) | WO2018232094A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970205B1 (fr) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation |
AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
SG11202107389SA (en) * | 2019-01-29 | 2021-08-30 | Shandong Xuanzhu Pharma Co Ltd | Hexone glucokinase inhibitor and use thereof |
US20220242870A1 (en) * | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
EA202193049A1 (ru) * | 2019-05-21 | 2022-02-14 | Вороной Инк. | N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака |
GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
JP2023554398A (ja) * | 2020-12-21 | 2023-12-27 | バイオクリスト ファーマスーティカルズ,インコーポレイテッド | 経口alk2キナーゼ阻害剤のための投薬レジメン |
WO2022251188A2 (fr) * | 2021-05-25 | 2022-12-01 | Biocryst Pharmaceuticals, Inc. | Inhibiteurs de la kinase alk2 contenant de l'imidazole |
WO2023198114A1 (fr) * | 2022-04-13 | 2023-10-19 | 杭州邦顺制药有限公司 | Inhibiteur de kinase alk2 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1990013332A1 (fr) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Support pour medicaments a liberation progressive |
EP0470246B1 (fr) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Prothese pour l'elution intraluminale d'un medicament |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
MXPA02003140A (es) * | 1999-11-22 | 2002-09-30 | Warner Lambert Co | Quinazolinas y su uso para la inhibicion de las enzimas cinasa dependientes del ciclin. |
AU2001266505A1 (en) * | 2000-06-28 | 2002-01-08 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
EP1317452B1 (fr) | 2000-09-15 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Composes pyrazole utiles comme inhibiteurs de la proteine kinase |
US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
WO2004081000A1 (fr) | 2003-03-10 | 2004-09-23 | Astrazeneca Ab | Dérivés quinazoliniques |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
JP2008525422A (ja) | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
SI2041138T1 (sl) * | 2006-07-07 | 2014-08-29 | Bristol-Myers Squibb Company | Pirolotriazin kinazni inhibitorji |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US20100311965A1 (en) | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
CA2737217A1 (fr) * | 2008-09-30 | 2010-04-08 | Astrazeneca Ab | Inhibiteurs heterocycliques de la kinase jak |
EP4198022A1 (fr) * | 2009-06-12 | 2023-06-21 | Abivax | Préparation des composés utiles pour le traitement du sida |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
WO2014105958A2 (fr) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Composés pyrimidine fusionnés et leur utilisation |
EP2970205B1 (fr) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2018
- 2018-06-13 AR ARP180101628A patent/AR112027A1/es unknown
- 2018-06-14 EA EA202090052A patent/EA202090052A1/ru unknown
- 2018-06-14 MX MX2019015226A patent/MX2019015226A/es unknown
- 2018-06-14 BR BR112019026517-1A patent/BR112019026517A2/pt unknown
- 2018-06-14 MA MA049401A patent/MA49401A/fr unknown
- 2018-06-14 US US16/622,816 patent/US11661426B2/en active Active
- 2018-06-14 AU AU2018283053A patent/AU2018283053C1/en active Active
- 2018-06-14 CN CN201880052585.8A patent/CN110913855A/zh active Pending
- 2018-06-14 JP JP2019568599A patent/JP7257338B2/ja active Active
- 2018-06-14 SG SG10202112496SA patent/SG10202112496SA/en unknown
- 2018-06-14 WO PCT/US2018/037503 patent/WO2018232094A1/fr active Application Filing
- 2018-06-14 EP EP18816547.6A patent/EP3638229A4/fr active Pending
- 2018-06-14 CA CA3066164A patent/CA3066164A1/fr active Pending
-
2019
- 2019-12-02 IL IL271109A patent/IL271109A/en unknown
- 2019-12-10 PH PH12019502781A patent/PH12019502781A1/en unknown
- 2019-12-13 MX MX2023004309A patent/MX2023004309A/es unknown
- 2019-12-13 CL CL2019003669A patent/CL2019003669A1/es unknown
-
2020
- 2020-01-09 CO CONC2020/0000194A patent/CO2020000194A2/es unknown
-
2022
- 2022-08-29 AU AU2022221581A patent/AU2022221581A1/en active Pending
-
2023
- 2023-02-13 US US18/168,055 patent/US20230271975A1/en active Pending
- 2023-04-03 JP JP2023060086A patent/JP2023082149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10202112496SA (en) | 2021-12-30 |
TW201904958A (zh) | 2019-02-01 |
AU2018283053C1 (en) | 2023-03-02 |
AU2018283053B2 (en) | 2022-09-08 |
IL271109A (en) | 2020-01-30 |
MX2019015226A (es) | 2020-08-03 |
KR20200028939A (ko) | 2020-03-17 |
AU2022221581A1 (en) | 2022-09-22 |
US20220332723A1 (en) | 2022-10-20 |
CA3066164A1 (fr) | 2018-12-20 |
EP3638229A1 (fr) | 2020-04-22 |
JP2023082149A (ja) | 2023-06-13 |
EA202090052A1 (ru) | 2020-05-22 |
JP7257338B2 (ja) | 2023-04-13 |
CN110913855A (zh) | 2020-03-24 |
CL2019003669A1 (es) | 2020-05-22 |
BR112019026517A2 (pt) | 2020-07-21 |
CO2020000194A2 (es) | 2020-04-24 |
US20230271975A1 (en) | 2023-08-31 |
EP3638229A4 (fr) | 2021-03-03 |
PH12019502781A1 (en) | 2020-10-26 |
AU2018283053A1 (en) | 2020-01-16 |
AR112027A1 (es) | 2019-09-11 |
US11661426B2 (en) | 2023-05-30 |
WO2018232094A1 (fr) | 2018-12-20 |
JP2020523351A (ja) | 2020-08-06 |
MX2023004309A (es) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49401A (fr) | Inhibiteurs de la kinase alk2 contenant de l'imidazole | |
MA51616A (fr) | Inhibiteurs d'adn-pk | |
DK3710439T3 (da) | Kras g12c-hæmmere | |
IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
IL273428A (en) | Heterocyclic compounds as PAD inhibitors | |
IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
MA52413A (fr) | Inhibiteurs de cd73 | |
MA50456A (fr) | Formulations d'un inhibiteur de kinase trk macrocyclique | |
MA54411A (fr) | Compositions contenant de l'ibrutinib | |
CL2016003175A1 (es) | Compuestos de [1, 2, 4 ] triazol e imidazol sustituidos | |
MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
IL259863B (en) | Polycyclic compounds as inhibitors of proton tyrosine kinase | |
ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
MA51337A (fr) | Inhibiteurs spiro exo-aza de l'interaction ménine-mll | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
IL263089A (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
IL280641A (en) | Converted benzimidazoles as PAD4 inhibitors | |
MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton |